Baxter International Inc. (BAX)
| Market Cap | 11.78B -3.9% |
| Revenue (ttm) | 11.47B +5.4% |
| Net Income | -1.06B |
| EPS | -2.06 |
| Shares Out | 517.00M |
| PE Ratio | n/a |
| Forward PE | 10.82 |
| Dividend | $0.04 (0.18%) |
| Ex-Dividend Date | Aug 28, 2026 |
| Volume | 1,263,426 |
| Open | 23.05 |
| Previous Close | 23.02 |
| Day's Range | 22.71 - 23.16 |
| 52-Week Range | 15.73 - 30.00 |
| Beta | 0.59 |
| Analysts | Hold |
| Price Target | 28.73 (+26.06%) |
| Earnings Date | Oct 29, 2026 |
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies;... [Read more]
Financial Performance
In 2025, Baxter International's revenue was $11.24 billion, an increase of 5.72% compared to the previous year's $10.64 billion. Losses were -$957.00 million, 47.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for BAX stock is "Hold." The 12-month stock price target is $28.73, which is an increase of 26.06% from the latest price.
News
Baxter International Transcript: Wells Fargo 21st Annual Healthcare Conference
Decentralization, continuous improvement, and debt reduction are driving operational and financial progress, with new leadership and product innovation supporting future growth. Business segments show mixed performance, but stability and targeted investments position the company for long-term value creation.
Baxter Appoints John Rogers Chief Financial Officer
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (C...
Baxter Announces Pricing for Its Upsized Cash Tender Offers
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the pricing terms for its previously announced cash tender offers (each, an “Offer” a...
Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early results of its previously announced cash tender offers (each, an “Offer” an...
Baxter Announces Cash Tender Offers
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Off...
Baxter International Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations with 5% organic revenue growth and strong free cash flow. Adjusted EPS guidance was raised due to a one-time tariff refund, while ongoing supply and macroeconomic risks are being closely monitored.
Baxter International Earnings release: Q2 2026
Baxter International released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Baxter International Slides: Q2 2026
Baxter International has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Baxter International Quarterly report: Q2 2026
Baxter International has published its Q2 2026 quarterly earnings report on July 30, 2026.
Baxter raises annual profit forecast on strong demand for IV solutions
Medical products maker Baxter International on Thursday raised its annual profit forecast and beat Wall Street estimates for quarterly results, banking on robust sales of its medical products such a...
Baxter Reports Second-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026. “Our second-quarter results exceeded expectation...
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, ...
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and r...
Baxter International Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a stabilization year with flat to low single-digit growth, operational improvements, and a focus on reducing leverage below 3x. Strategic priorities include continuous improvement, margin expansion, and flexible capital allocation as the business prepares for renewed growth next year.
Baxter International Transcript: Bank of America Global Healthcare Conference 2026
Management detailed ongoing cultural and operational transformation, emphasizing accountability, decentralized decision-making, and improved incentive alignment. Portfolio stabilization, margin expansion, and free cash flow improvement are key priorities, with capital allocation flexibility expected once leverage falls below 3x.
Baxter International Transcript: AGM 2026
The meeting covered board updates, five key proposals, and voting outcomes. All proposals, including director elections, executive compensation, auditor ratification, incentive plan, and board size amendment, were approved by strong majorities. Final results will be filed on Form 8-K.
Baxter International Earnings Call Transcript: Q1 2026
First quarter results were in line with expectations, with reported sales up 3% but organic sales down 1% and adjusted EPS down 35% year-over-year. Guidance for 2026 is reiterated, with flat organic sales and improved performance expected in the second half, supported by new product launches and operational improvements.
Baxter International Slides: Q1 2026
Baxter International has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Baxter International Earnings release: Q1 2026
Baxter International released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Baxter International Quarterly report: Q1 2026
Baxter International has published its Q1 2026 quarterly earnings report on April 30, 2026.
Baxter beats quarterly expectations on strong demand for medical devices
Baxter on Thursday beat Wall Street estimates for first-quarter profit and revenue, helped by robust sales in its medical products and therapies unit.
Baxter Reports First-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were ...
Baxter International Proxy statement: Proxy filing
Baxter International filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolio...